Kyntra Bio KYNB
NASDAQ KYNB
$3.20 -0.29 (-8.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Kyntra Bio (KYNB) Gains (Losses) on Sale of Assets & Investments (2026)

Updated

Analysis

Kyntra Bio (KYNB) Gains (Losses) on Sale of Assets & Investments (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn -
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn -
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn -
10 Kyntra Bio 12.57 Mn -395.37 Mn 1.47 Mn 30.94 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 30.94 Mn
API Access

Kyntra Bio Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=KYNB&period=max&api_key=YOUR_API_KEY